Newsroom

Stay informed

All

Stories

Events

26 Articles

Jun 2026Synthon Announces Strategic Expansion in Spain

May 2026Synthon receives EU grant to strengthen R&D capabilities in Blansko

Apr 2026Synthon: Benelux Deal of the Year – Real Deals

Sep 2025Zydus and Synthon entered into exclusive licensing and supply agreement for Ozanimod Capsules for the U.S. market

Zydus Lifesciences Ltd. (including its subsidiaries and affiliates), a global innovation-driven healthcare company, announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE, has entered into an exclusive licensing and supply agreement with Synthon BV of the Netherlands for Ozanimod Capsules (a generic version of ZEPOSIA®) for the U.S. market. Synthon has a pending abbreviated new drug application in the United States, seeking approval for Ozanimod Capsules indicated for relapsing forms of multiple sclerosis.

Jun 2025Synthon Announces Investment from Goldman Sachs Alternatives

Nijmegen, 16th June 2025 – Today, Synthon (the “Company”) a leading platform specialized in developing, manufacturing, and out-licensing complex generic medicines, announced an investment from Private Equity at Goldman Sachs Alternatives. This represents the acquisition of a majority stake in the Company from funds advised by BC Partners, who will continue to own a significant stake in the Company.

Jan 2023Silver Medal in EcoVadis Assessment 2024Stories

Synthon Awarded Silver Medal in 2024 EcoVadis Sustainability Assessment

Synthon, is proud to announce that it has been awarded the prestigious Silver Medal in this year’s EcoVadis sustainability assessment, reflecting the company’s unwavering commitment to responsible business practices and environmental stewardship.

15 April, 2024Leaders in Life Sciences Podcast Synthon CEO Anish Mehta shares his career journey, leadership insights, and strategic vision for the future of generic medicines in an engaging conversation with Henk Jan Out on the Leaders in Life Sciences Podcast. Click here to tune in to gain valuable perspectives on innovation, market challenges, and Synthon’s role in advancing the pharmaceutical industry. Events

Jan 2024Zydus and Synthon enter into an exclusive licensing and supply agreement for Palbociclib Tablets for the US marketZydus Lifesciences Ltd., a global innovation driven healthcare company announced that its wholly owned subsidiary, Zydus Worldwide DMCC, has entered into an exclusive licensing and supply agreement with Synthon BV for Palbociclib Tablets (a generic version of IBRANCE®) for the US market.Stories

Dec 2023Synthon celebrates second year of support for Amalia's Kinderziekenhuis Synthon proudly announces its continued support for Amalia's Kinderziekenhuis for the second consecutive year. Our company is happy to reveal a total of €12,164 raised during the recent fundraising campaign.Stories

Nov 2023CPHI 2023 was a great successThank you for another successful CPHI. For the past three days, our committed team met with customers, suppliers and potential new partners from the international pharmaceutical industry. Thank you all for these successful days. We can't wait to see you again next year!Stories

Jun 2023Synthon announces successful bioequivalence studies for Bempedoic acidSynthon is proud to announce the completion of two successful bioequivalence (BE) studies for Bempedoic acid, a product we are developing for our valued partners.Stories

Jan 2023Extension Synthon HispaniaSynthon keeps growing. With our extension of Synthon Hispania, we will enhance our R&D capacity and expand our production capacity.Stories